Survival benefits from afatinib compared with gefitinib and erlotinib among patients with common EGFR mutation in first‐line setting
WC Kwok, JCM Ho, TCC Tam, MSM Ip… - Thoracic …, 2022 - Wiley Online Library
Background Epidermal growth factor receptor‐tyrosine kinase inhibitors (EGFR‐TKIs) are
recommended as first‐line treatment in non‐small cell lung cancer (NSCLC) patients with …
recommended as first‐line treatment in non‐small cell lung cancer (NSCLC) patients with …
Which of afatinib and gefitinib/erlotinib is the better EGFR-TKI to be followed by osimertinib?
M Tamiya, A Tamiya, H Suzuki… - Annals of …, 2018 - annalsofoncology.org
Background: In epidermal growth factor receptor (EGFR) mutation-positive non-small cell
lung cancer (NSCLC), there are various treatment challenges. Most patients develop …
lung cancer (NSCLC), there are various treatment challenges. Most patients develop …
[HTML][HTML] A retrospective comparison of the clinical efficacy of gefitinib, erlotinib, and afatinib in Japanese patients with non-small cell lung cancer
A Fujiwara, M Yoshida, H Fujimoto, H Nakahara… - Oncology …, 2018 - ncbi.nlm.nih.gov
Tyrosine kinase inhibitors (TKIs) are very effective against non-small cell lung cancer
(NSCLC) caused by epidermal growth factor receptor (EGFR) mutation. Before the approval …
(NSCLC) caused by epidermal growth factor receptor (EGFR) mutation. Before the approval …
Phase II study of the EGFR-TKI rechallenge with afatinib in patients with advanced NSCLC harboring sensitive EGFR mutation without T790M: Okayama lung cancer …
N Oda, E Ichihara, K Hotta, K Ninomiya, T Ninomiya… - Clinical Lung Cancer, 2017 - Elsevier
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) as first-line therapy
for patients with EGFR-mutated non–small-cell lung cancer (NSCLC) have shown a …
for patients with EGFR-mutated non–small-cell lung cancer (NSCLC) have shown a …
A phase I trial of afatinib and bevacizumab in chemo-naïve patients with advanced non-small-cell lung cancer harboring EGFR mutations: Okayama Lung Cancer …
T Ninomiya, N Nogami, T Kozuki, D Harada, T Kubo… - Lung Cancer, 2018 - Elsevier
Objective In advanced epidermal growth factor receptor (EGFR)-mutant non-small-cell lung
cancer (NSCLC), treatment with afatinib, a second-generation EGFR-tyrosine kinase …
cancer (NSCLC), treatment with afatinib, a second-generation EGFR-tyrosine kinase …
Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first‐line gefitinib, erlotinib and afatinib‐treated non‐small cell lung …
YT Lin, JS Chen, WY Liao, CC Ho… - … Journal of Cancer, 2019 - Wiley Online Library
Gefitinib, erlotinib and afatinib are approved for first‐line treatment of advanced non‐small
cell lung cancer (NSCLC) bearing an activating epidermal growth factor receptor (EGFR) …
cell lung cancer (NSCLC) bearing an activating epidermal growth factor receptor (EGFR) …
[HTML][HTML] The efficacy and toxicity of afatinib in advanced EGFR-positive non-small-cell lung cancer patients after failure of first-generation tyrosine kinase inhibitors: a …
Y Zhang, S Miao, F Wang, W Fang, G Chen… - Journal of Thoracic …, 2017 - ncbi.nlm.nih.gov
Background The first generation epidermal growth factor receptor-tyrosine kinase inhibitors
(EGFR-TKIs), gefitinib and erlotinib, have become the standard first-line treatment for non …
(EGFR-TKIs), gefitinib and erlotinib, have become the standard first-line treatment for non …
Real-world outcomes of first-and second-generation tyrosine kinase inhibitors first-line in patients with epidermal growth factor receptor mutation-positive non-small …
WW Ng, CC Lin, CY Cheng, JS Jiang, SJ Kao, DY Yeh - Plos one, 2021 - journals.plos.org
The sequencing of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs)
in patients with EGFR mutation-positive (EGFRm+) non-small cell lung cancer (NSCLC) …
in patients with EGFR mutation-positive (EGFRm+) non-small cell lung cancer (NSCLC) …
Re-challenge of afatinib after 1st generation EGFR-TKI failure in patients with previously treated non-small cell lung cancer harboring EGFR mutation
O Yamaguchi, K Kaira, A Mouri, A Shiono… - Cancer chemotherapy …, 2019 - Springer
Background Re-challenge of erlotinib after gefitinib failure is reported to yield some benefit
in patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor …
in patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor …
[HTML][HTML] Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial
L Paz-Ares, EH Tan, K O'Byrne, L Zhang, V Hirsh… - Annals of …, 2017 - Elsevier
ABSTRACT Background In LUX-Lung 7, the irreversible ErbB family blocker, afatinib,
significantly improved progression-free survival (PFS), time-to-treatment failure (TTF) and …
significantly improved progression-free survival (PFS), time-to-treatment failure (TTF) and …
相关搜索
- egfr mutation gefitinib and erlotinib
- survival benefits gefitinib and erlotinib
- gefitinib erlotinib egfr tki
- gefitinib erlotinib japanese patients
- gefitinib erlotinib retrospective comparison
- gefitinib erlotinib clinical efficacy
- gefitinib in patients lung cancer
- afatinib and bevacizumab lung cancer
- t790m mutation clinical outcomes
- egfr mutation survival benefits
- egfr mutations lung cancer
- egfr mutation afatinib in patients
- egfr mutations afatinib and bevacizumab
- egfr mutations clinical outcomes
- afatinib in patients egfr tki
- gefitinib in patients lux lung